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Abstract 
Cell signaling by the c-Src proto-oncogen requires the attachment of the protein to the inner side of the plasma 
membrane through the myristoylated N-terminal region, known as the SH4 domain. Additional binding regions of lower 
affinity are located in the neighbor intrinsically disordered Unique domain and the structured SH3 domain. Here we 
present a surface plasmon resonance study of the binding of a myristoylated protein including the SH4, Unique and SH3 20 
domains of c-Src to immobilized liposomes. Two distinct binding processes were observed: a fast and a slow one. The 
second process lead to a persistently bound form (PB) with a slower binding and a much slower dissociation rate than 
the first one. The association and dissociation of the PB form could be detected using an anti-SH4 antibody. The kinetic 
analysis revealed that binding of the PB form follows a second order rate law suggesting that it involves the formation 
of c-Src dimers on the membrane surface. A kinetically equivalent PB form is observed in a myristoylated peptide 25 
containing only the SH4 domain but not in a construct including the three domains but with a 12-carbon lauroyl 
substituent instead of the 14-carbon myristoyl group. The PB form is observed with neutral lipids but its population 
increases when the immobilized liposomes contain negatively charged lipids. We suggest that the PB form may 
represent the active signaling form of c-Src while the labile form provides the capacity for fast 2D search of the target 
signaling site on the membrane surface. 30 
 
 
Highlights 
• Myristoylated c-Src bind to membranes in two forms kinetically distinguishable by SPR 
• A persistently bound form of c-Src was studied by SPR using an anti-SH4 antibody. 35 
• Formation of the persistently bound only requires the myristoylated SH4 domain. 
• A fatty acid chain of at least 14 carbons is required for persistent binding.  
• The persistently bound species is a c-Src dimer formed on the membrane.  
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Introduction 
 
c-Src is the leading member of the Src family of non-receptor tyrosine kinases, (SFKs), which are involved in many 
signaling pathways [1] [2] [3]. The deregulation of these kinases, and in particular c-Src, affects cell migration, 
proliferation and survival [4]. Src is over expressed or up regulated in several tumor types, including colorectal (CRC) 50 
and prostate cancers [5] [2] and has been associated with the survival of bone metastasis breast cancer cells [6]. In 
addition, high activity levels of Src and the related kinase Yes have been linked to poor clinical prognosis [7] [8]. 
The N-terminal (SH4) region of c-Src is cotranslationally myristoylated at the N-terminal glycine residue and is rich in 
charged residues. The SH4 domain serves as a membrane-anchoring point. In its resting state, c-Src is localized near the 
perinuclear region and probably associated to endosomes [9], and is translocated to the cytoplasmic side of the plasma 55 
membrane upon stimulation [10]. Downstream signaling of c-Src depends on its sub cellular localization. c-Src activity 
causes RhoA inhibition at focal adhesion sites [2]
 
but activation of the same protein at podosomes [11].	 c-Src also 
participates in the formation of lamellipodia at the leading edge of migrating cells [12]. Proliferation and survival are 
mediated by c-Src through the RAS-MAPK and PIK3-Akt signaling pathways. The involvement of c-Src in such a 
variety of pathways reflects an exquisite spatial and temporal regulation of this molecule.  60 
Most SFKs are both palmitoylated and myristoylated, but c-Src contains only one myristoyl group [13]. While the 
insertion of the single myristoyl chain provides barely enough hydrophobic energy to attach the protein to the lipid 
bilayer, concurrent hydrophobic and electrostatic interactions result in effective[14], although reversible, membrane 
anchoring[15].	A	soluble pool of c-Src has been reported in several cell types (e.g. Cos-7, Swiss T3T cells) [16] [17] 
[18]. Fluorescence recovery after photobleaching of c-Src-GFP demonstrated the trafficking of c-Src between the 65 
plasma membrane and endosomes was fast and independent of actin and tubulin, thereby suggesting that c-Src 
trafficking involves short-term cytosolic release (“hopping”) [15]. Non-vesicular transport has also been observed for 
non-palmitoylated Ras[19], although the recovery rate of Src-GFP fluorescence observed by Kashahara et al. [15] was 
slower than that of the non-palmitoylated Ras [19].  
Surface plasmon resonance (SPR) is widely used for the characterization of the kinetics and thermodynamics of binding 70 
of macromolecules to immobilized receptors [20], lipids [21] or even entire cells [22]. Using SPR, here we show that c-
Src anchoring involves two kinetically well-separated events, namely: a rapid reversible binding step followed by the 
formation of a persistently bound (PB) species. Kinetics modeling of the build-up of the slowly dissociating species is 
consistent with the formation of c-Src dimers inserted in the membrane.  
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Materials and Methods 
 
Cloning, expression and purification  
The dual gene expression vector pETDuet-1 (Novagen), which comprises two cloning sites, was provided by Julian M. 
Glück [23]. The N-Myristoyl Transferase (NMT) gene was already introduced into the first site. The gene encoding the 80 
first 185 residues of c-Src, from now on called USH3 was cloned in the second site. USH3 comprises the SH4, Unique 
and SH3 domains, followed by a His6 purification tag. 
USH3 protein expression was performed in Escherichia coli RosettaTM (DE3)pLysS cells (Novagen). The protocol 
described by Glück et al. [23] gave a mixture of non-acylated forms, laurylated forms, myristoylated forms coeluting 
with NMT and not separable from it, and a degraded form. To obtain pure myristoylated USH3 (MyrUSH3), we 85 
modified the protocol. Just before induction with isopropyl-β-D-thiogalactopyranosid (Melford) at final concentration 
of 1 mM, myristic and palmitic acid (Sigma) were added to the cell culture, at a final concentration of 200µM. The cell 
pellet was resuspended in lysis buffer (20mM TrisHCl, 300mM NaCl, 5mM Imidazole, pH 8), to which protease 
inhibitors were added (Protein Inhibitor Cocktail1, and 1mM PMSF, both from Sigma). Cells were sonicated and 
centrifuged. The supernatant contained the previously described mixture, but pure MyrUSH3 was retained in the pellet, 90 
and subsequently extracted using lysis buffer supplemented with 1% Triton X100 (Sigma). The non-acylated and 
degraded forms, which do not contain the myristoyl group, were not retained in the pellet. Further purification was 
performed in a Ni-NTA column (Qiagen) followed by size exclusion chromatography in a Superdex 75 26/60, in 
phosphate buffer (50mM NaP, 150mM NaCl, 0.2mM EDTA, pH 7,5). The purity and identity of the product was 
established by HPLC and mass spectrometry (BioSuite pPhenyl 1000RPC 2.0 x 75 mm coupled to a LCT-Premier 95 
                                                            
1 
   Protein cocktail inhibitor: 23 mM AEBSF, 1mM EDTA, 20 µM Bestatin,  3 µM Pepstatin A, 3 µM E64 (final 
concentrations in lysis buffer) 
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Waters from GE Healthcare). 
Laurylated USH3 (LaurUSH3) was obtained as a side product during protein expression in E. coli as a result of the low 
selectivity of yeast NMT towards the shorter chain acyl CoA forms resulting from the β-oxidation of longer fatty acids. 
Given that palmitoyl CoA is not a good substrate of NMT but is metabolized to myristoyl CoA, the addition of palmitic 
acid reduced the undesired laurylation of the protein. LaurUSH3 was separated from MyrUSH3 by size exclusion 100 
chromatography, and its purity was verified by HPLC and MS. 
Myristoylated SH4 (MyrSH4) was synthesized using standard solid-phase methods. 
 
Liposome preparation 
All lipids were from Tebubio. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-105 
phosphocholine, DOPC, and 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt), DOPG were dissolved 
in chloroform. 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DMPG) was dissolved in 
chloroform:methanol:H2O 65:35:8. Three lipid compositions were used, DMPC alone, DMPC:DMPG 2:1 or 
DOPC:DOPG 2:1. The dissolved lipids were evaporated in a rotavapor, and lipid films were rehydrated with buffer 
(50mM NaP, 150mM NaCl, 0.2mM EDTA, pH 7.5) by warming the lipid film at 40ºC and vortexing, rendering a final 110 
total lipid concentration of 1 mM. Large unilamellar vesicles were prepared by mechanical extrusion using a 10-mL 
Thermobarrel extruder (LipexTM. Northerns Lipids Inc.). The lipid suspension was extruded repeatedly (10 times) 
through a 100 nm polycarbonate filter at 40ºC. To verify the appropriate size of the liposomes, the mean diameter was 
checked using Dynamic Light Scattering (Zetasizer Nanoseries S, Malvern instruments). 
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Direct SPR binding assay 
SPR experiments were carried out in a Biacore 100 instrument from GE Healthcare. The SPR chip (a 2D 
carboxymethyldextran surface) from Xantec was modified by covalent attachment of phytosphingosine (TebuBio) to 
allow the capture of neutral or negatively charged liposomes containing DMPC or DMPC-DMPG (2:1), respectively. 
Experiments were carried out at 298K where these lipids and lipid mixtures are in the liquid crystalline phase. Control 120 
experiments with the equivalent unsaturated oleyl lipids DOPC-DOPG (2:1) with a transition temperature of 256 K-256 
K gave very similar results (Figure S6). The reference channel was blocked with BSA, with a  1 mg/ml injection at 
10µl/min for 100 s. The immobilization protocol and subsequent liposome coating were performed in the instrument 
chamber, at a flow rate of 10 µl/min. To minimize mass transport phenomena, a flow rate of 50 µl/min was used to 
monitor the interaction of MyrUSH3 with liposomes. The SPR response of MyrUSH3 binding to liposomes was 125 
followed for 60 s (association phase), while the subsequent washing lasted 200 s (dissociation phase). Protein 
concentration ranged from 1 µM to 20 µM, and all experiments were performed in the running buffer, which comprised 
50 mM NaP, 150 mM NaCl and 0.02 mM EDTA, pH 7.5, unless indicated otherwise. The surface was regenerated with 
a 10-mM HCl pulse followed by a 20-mM CHAPS pulse, both for 30 s at 10 µl/min. Each experiment was started with 
freshly captured liposomes. The liposome coating itself was reproducible, reaching an average value of 6785 RU 130 
(standard deviation 625 RU) for DMPC liposomes, and 8193 RU (standard deviation 608 RU) for DMPC:DMPG 
liposomes, guaranteeing reproducible protein responses as shown in Figure 4. 
 
SPR detected antibody capture 
MyrUSH3 dissociated very quickly from liposomes, but the presence of a residual population of lipid bound MyrUSH3 135 
was detected by the SPR response observed after injecting antiSH4 antibody (Abcam) at a 1:10 dilution in the running 
buffer. The association and dissociation kinetics of these PB species were studied separately: dissociation was measured 
by recording the antibody response at increasing times after a constant association time of 60 s, while association was 
monitored by detecting the antibody response at a fixed time after the end of increasingly long association times. The 
flow rate was kept at 50 µl/min during protein association and dissociation, and decreased to 30 µl/min just before 140 
antibody injection.   
 
Model and data analysis 
Direct SPR responses of MyrUSH3 binding to liposomes were analyzed using the Biaevaluation software from Biacore 
using two alternative models: the 1:1 model and the conformational change model. Data of the PB fraction, obtained by 145 
antiSH4 antibody secondary detection, were analyzed using Igor software, with the models described in the results 
section. All data were double referenced (reference channel and baseline subtraction). 
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Direct SPR data from MyrUSH3 binding to liposomes were initially fitted with a simple 1:1 Langmuir model described 
by reaction 1.  
P + L     ó      PL (ka and kd)  reaction (1) 150 
where P represents the MyrUSH3 protein, L the lipids, and PL the lipid-bound protein, the latter forming with the 
association and dissociation rate constants  ka  and kd  respectively. 
The SPR response is proportional to [PL], obeying the equation: 
[PL](t) = Leq.(1 – exp(-(ka.[P]+kd).t))   eq. (1) 
with Leq = Lmax (ka. [P]/(ka.[P]+kd))   eq. (2) 155 
The amount of immobilized liposomes limits the highest possible protein response, proportional to Lmax. The rate 
constants can be estimated by globally fitting the binding curves at various concentrations. The association constant Ka 
can be obtained from the ratio of rate constants Ka = ka/kd. 
Ka can also be obtained by fitting the equilibrium SPR responses (Leq) obtained at various protein concentrations [P]. In 
the 1:1 Langmuir model, the relevant equation is a modification of equation (2):  160 
Leq = Lmax ([P]/([P]+1/Ka))   eq. (3) 
 
 
Results 
 165 
MyrUSH3 contains the first three domains of c-Src: the polybasic peptide SH4, the intrinsically disordered Unique 
Domain and the SH3 domain (Figure 1). The SH4 domain is myristoylated at its N-terminal and is the primary 
membrane-anchoring point of c-Src. The Unique and SH3 domains contain additional lipid binding regions [24]. 
MyrUSH3 was obtained in E. coli cells by co-expression with yeast N-Myristoyl Transferase. Figure 1a shows the 
domain structure of full-length Src and Figure 1b the amino acid sequence of the USH3 construct used in this study, 170 
highlighting the three lipid binding regions SH4, Unique Lipid Binding Region (ULBR) and the RT loop in the SH3 
domain.  
 
Persistent binding of MyrUSH3 to liposomes  
MyrUSH3 binding to immobilized DMPC, DMPC:DMPG or DOPC:DOPG liposomes was followed by SPR at 298K. 175 
These lipid systems are in the fluid phase under these conditions. This approach consisted of the following steps: i) 
liposome immobilization; ii) injection of MyrUSH3 (association phase); iii) washing with a protein-free buffer 
(dissociation phase); iv) antiSH4 antibody injection; and v) surface regeneration by washing away the liposomes. A 
complete cycle of MyrUSH3 binding to DMPC:DMPG liposomes is shown in Supplementary Material (Figure S.1). 
The association phase revealed rapid binding and equilibrium was reached quickly. The response curve also revealed a 180 
rapid dissociation. However, the baseline did not return to its original value (the liposome capture value), but remained 
stable at a slightly higher level, thereby indicating the presence of PB MyrUSH3 proteins that were not removed by 
washing with the running buffer. Due to the small population of PB species, a secondary detection was used to confirm 
their presence and to quantify them. In this regards, 350 s after the beginning of the dissociation phase, antiSH4 
antibody was injected over 60 s. As a control, the antibody was also injected over protein free liposomes. In this case, 185 
no response was observed: MyrUSH3 and antiSH4 antibody were completely removed with the lipids when applying 
the regeneration conditions as described in the method section.  
 
Electrostatic and hydrophobic components of MyrUSH3 binding to DMPC:DMPG liposomes. 
The myristoylated N-terminal region of c-Src is known to be essential for binding but the PB population had not 190 
previously been reported. In order to check whether persistent binding was caused by the presence of additional lipid 
binding outside the myristoylated SH4 domain, we measured the binding of a synthetic peptide, containing only 
residues 2-16 of c-Src with a myristoyl group attached at its N-terminus (MyrSH4), to liposomes. The presence of a PB 
MyrSH4 population was clearly observed by injection of antiSH4 antibody (Figure 2a). The affinity of the antibody for 
the two SH4 containing molecules may not be directly comparable, impairing comparison of the relative antibody 195 
responses of MyrSH4 or MyrUSH3 PB species. Nevertheless, we can still conclude that formation of the PB species is a 
property of the MyrSH4 domain and does not require the presence of the additional binding regions in the Unique and 
SH3 domains. The decrease of the direct SPR response curve during dissociation was slower in MyrSH4 than in 
MyrUSH3, thereby suggesting that the presence of the secondary lipid binding domains in USH3 enhances the 
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dissociation rate of the MyrSH4 region from the membrane. This apparently contradictory result may be explained by 200 
the recently reported interaction between the SH4 and SH3 domains of c-Src [25]. Since MyrUSH3 provides a more 
native-like environment and gives a stronger SPR response than MyrSH4, we focused our study on acylated USH3. The 
effect of myristoylation on the capacity of c-Src to bind membranes has been extensively discussed. It was concluded 
that the binding energy provided by the insertion of a single myristoyl chain was not sufficient to explain the stable 
insertion of c-Src in the membrane. However, the electrostatic interaction between the positively charged SH4 domain 205 
and negatively charged lipids, together with myristoyl chain insertion, was enough to ensure stable binding [26] [27] 
[28]. In order to explore the contribution of the hydrophobic and electrostatic components, we first compared the 
binding of MyrUSH3 and LaurUSH3 to liposomes. These two species differ only in the length of the N-terminal acyl 
chain with lauric acid having a 12-carbon chain and myristic acid a14-carbon chain.  
Figure 2b compares the binding of MyrUSH3 (1 µM and 20 µM) and LaurUSH3 (20 µM) to DMPC:DMPG liposomes. 210 
When the two proteins were injected at the same concentration (20 µM), the direct SPR response of LaurUSH3 was 
circa four times lower than that of MyrUSH3, and the secondary detection by antiSH4 antibody gave barely any 
response for LaurUSH3. In comparison, the injection of 1 µM MyrUSH3, which provided a direct SPR response half 
that of the 20 µM LaurUSH3 injection, still gave a clearly detectable antibody response. These experiments show that 
while shortening of the acyl chain clearly reduced, but did not eliminate, the binding of the fast dissociating form, it 215 
abolished the formation of PB species.  
The effect of the electrostatic interactions on the formation of PB MyrUSH3 species was first tested by comparing 
MyrUSH3 (10µM) binding to neutral (DMPC) or charged (DMPC:DMPG 2:1) liposomes. For negatively charged 
liposomes, the direct SPR response was higher, the dissociation was slower and the baseline recovered after washing 
was also higher. Secondary detection confirmed that the population of the PB forms was higher for MyrUSH3 bound to 220 
negatively charged lipids (Figure 2c). The electrostatic interaction of MyrUSH3 with charged liposomes increased at 
lower ionic strengths (Figure 2d). The direct SPR response was doubled when the salt concentration was reduced from 
150 mM to 0 mM, in 50 mM NaP. A markedly slower dissociation was observed at low ionic strength. Consistently, we 
observed a much stronger response to the antibody, about four times larger, thereby suggesting that the relative 
population of the PB forms with respect to rapidly dissociating ones is increased at low ionic strength. However, the 225 
decrease in the baseline to values lower than before the MyrUSH3 injection suggests that at low ionic strength, 
MyrUSH3 binding affects the immobilized liposomes. Consequently, we quantitatively analyzed the two binding 
processes presented below in the presence of 150 mM NaCl, a value close to physiological ionic strength.    
 
Kinetics analysis of the direct response of MyrUSH3 binding to liposomes 230 
MyrUSH3 binding was initially measured at protein concentrations ranging from 1 µM to 100 µM using the direct SPR 
response. Below 20 µM, the binding curves had the expected shape, with an association phase leading to a plateau when 
reaching equilibrium, followed by protein dissociation after washing with buffer. At concentrations higher than 20 µM, 
the binding curves did not reach a stable plateau after 60 s. Failure to reach a stable equilibrium, at high concentration 
may be due to slow binding or a cooperative binding of peptides over the lipid surface [30] - see Supplementary 235 
Materials, Figure S.2a. We chose to restrict our study to concentrations between 1 µM and 20 µM. 
The direct response of MyrUSH3 binding to liposomes was studied in order to obtain kinetics and affinity information 
on the fast associating and dissociating population. While the presence of multiple binding modes would in principle 
prevent the use of a simple model, the contribution of the PB form to this response was very small. We thus first 
analyzed the data with a simple 1:1 Langmuir model. From a formal point of view, peptides partition to liposomes, and 240 
stoichiometry is most often unknown. Nevertheless, simplification using the Langmuir model gives a satisfactory 
starting point for analyzing kinetics data obtained by SPR [31]. A reasonable fit of our experimental curves was 
obtained, especially for the association phase, although deviations were observed at the end of the dissociation phase. 
(see Supplementary Materials Figure S.2b). The association constant derived from the 1:1 Langmuir model (1.54 104 ± 
7.01 103 M-1) for the binding of MyrUSH3 to DMPC liposomes is in good agreement with the value (9*103 M-1) 245 
obtained by Buser et al. for MyrSH4 peptide using partition methods [27].  Binding to charged liposomes occurs with 
circa one order of magnitude higher affinity (1.9 105 ± 6.52 104 M-1), confirming the electrostatic contribution to the 
binding affinity. Kinetic and binding constants are given in Table S2 of the Supplementary Material.  
An improved fitting of the dissociation phase could be obtained with a conformational change model in the 
Biaevaluation software, which assumes two separate bound forms. Figure S.2b shows expansions comparing the 250 
experimental and best-fit curves for MyrUSH3 binding to neutral and charged liposomes using the two models. While 
the conformational change model improves the fitting of the (fast) processes that dominate the direct SPR response and 
points to the presence of more than one second form of bound MyrUSH3, the corresponding dissociation rates are too 
fast to explain the PB form observed after more than 60 s of dissociation.  
The existence of a persistently bound form of c-Src has strong biological implications and the characterization of the 255 
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nature and kinetics properties of MyrUSH3 is thus of great interest. 
 
 
Kinetics analysis of the PB form of MyrUSH3 binding to liposomes  
The observation of the PB form after extensive washing, a procedure that removed the fast dissociating population, 260 
offers the possibility to study association and dissociation kinetics of the two species independently. In addition, 
secondary detection by antiSH4 antibody capture provided the required sensitivity to study the binding kinetics of the 
PB form, which is much less populated and gives a low SPR signal.  
By varying the MyrUSH3 association time, and applying the antibody at a constant time after the association phase, we 
were able to follow the association kinetics of the PB form independently. In a similar manner, by keeping constant the 265 
association time of MyrUSH3 binding to liposomes, and applying the antibody at different times of the dissociation 
phase, we were able to independently study its dissociation. The experimental design is shown in Figure 3.  
Figure 4a and 4b show the experimental curves obtained by this method for a given association/dissociation time (60 
s/350 s). The antibody solution was injected at a constant dilution and therefore, the observed SPR response is assumed 
to reflect the population of MyrUSH3 present on the liposome surface. Indeed, the antibody response was greater with 270 
increasing the concentration of MyrUSH3 during the association phase. 
Figure 4c and 4d show the dissociation phase of the PB form of MyrUSH3 bound to neutral and charged liposomes. 
Dissociation from neutral liposomes is negligible in the observed time frame and very slow from charged liposomes. 
The population of MyrUSH3 that remains bound to neutral DMPC liposomes did not decrease between 400 and 7200 s 
after the end of the association phase. In the case of DMPC:DMPG liposomes, the bound population of MyrUSH3 after 275 
400 s was higher than with neutral lipids and slowly decreased between 400 and 7200 s. After 2 h, the population of 
MyrUSH3 bound to neutral and charged liposomes reached a plateau, suggesting that a fraction of this form became 
irreversibly bound to both types of liposomes. 
On the light of the above observations, the process leading to the appearance of the PB form was analyzed using a 
"conformational change"-like model in which PL gives rise to PB in an irreversible manner. The rate constant of the 280 
transformation of PL to PB is designated as k'on. 
 
P + L   ó      PL     (ka and kd) reaction (1) 
 
  PL      ð    PB   (k'on)  reaction (2) 285 
 
The model is presented using generic lipid containing species [L]; however the actual stoichiometry of the interaction is 
not known. For this reason we write the derived equations in terms of the fraction of lipids bound to protein, θ. 
 
θ = [PL]/Lmax + [PB]/Lmax    eq. (4) 290 
 
1-θ = [L]/Lmax     eq. (5) 
 
Since the amount of PB formed is small compared to that of PL, we assume that the kinetics of the formation of  PB 
does not modify the equilibrium of PL:  295 
 
θ ~ [PL]/Lmax     eq. (6) 
 
This hypothesis explains the (experimentally observed) dependence of the binding levels with protein concentration. 
Without this hypothesis, the maximum concentration of [PB] would be the same for all concentrations in our equations, 300 
due to the irreversibility of the second equation. 
 
 
Assuming reaction (1) is at equilibrium, we can derive an expression of θ. 
 305 
θ = Ka.[P]/(1+Ka.[P])   eq. (7) 
 
We want to solve the kinetics equation corresponding to reaction (2) 
 
d[PB]/dt = k'on.[PL]    eq. (8) 310 
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In terms of occupation  
 
dθPB/dt = k'on.θPL    eq. (9) 
 315 
Resolution of equation (9) is detailed in Supplementary Material S.4. The following expression is obtained: 
 
θPB = θ.(1-exp(-k'on.t))   eq. (10) 
 
We call R the SPR response of the antiSH4 antibody binding to PB, which  is proportional to [PB]. 320 
 
R = C1.(1-exp(-k'on.t))   eq. (11) 
 
with C1  proportional to θ. Lmax . 
 325 
We fitted equation (11) locally to the experimental curves obtained at various concentrations. The best-fit values are 
displayed in Figure 5a for DMPC and Figure 5b for DMPC:DMPG. In the Supplementary Material, Table S.4 gives the 
values of the best-fit parameters. 
We observe that k’on depends linearly on protein concentration (Figure 5c-5d).  
 330 
This concentration dependence of the apparent rate constants for the conversion between the initially (and reversibly) 
bound form of MyrUSH3 to the PB form is an experimental indication that the conversion between the two forms of is a 
bimolecular process and suggests that the PB species of MyrUSH3 are, at least, dimeric forms.  
 
Dimerization can be explicitly included in the binding model, assuming that PL can interact with a second P molecule 335 
to form PB, which we now explicitly label as PB2 to stress its dimeric nature, with an association rate constant kon: 
 
P + L     ó     PL  (ka and kd) reaction (1) 
 
PL + P    ð   PB2  (kon)  reaction (4)  340 
 
In this case, θPB2 can be expressed as:  
 
θPB2= θ.(1-exp(-kon.[P].t))   eq. (12) 
 345 
Fitting using equation (11)  is equally applicable but in this case 
 
k'on = kon.[P]    eq. (13) 
 
The bimolecular kon (unit M-1.s-1) can be obtained from the slope of the linear fit between k'on and the protein 350 
concentration [P]. For DMPC liposomes,  kon = 1.2*104 M-1.s-1, while for DMPC:DMPG liposomes, kon = 5.1*103 M-1s-1 
The kon value obtained with this model for neutral liposomes is larger than for charged ones. From the fitted kon values it 
is possible to estimate and compare the true velocity of the PB species formation on both types of liposomes and at 
different protein concentrations. According to our model, the velocity v is given by: 
 355 
v = k'on.Req    eq. (14) 
 
where Req is the direct SPR response at equilibrium (in Response Units) 
 
The ratio of velocities of PB species formation in DMPC:DMPG versus DMPC alone, plotted as a function of protein 360 
concentration [P], can be found in the Supplementary Material (Figure S.5). At low concentration, the formation is 
faster in charged liposomes, but the ratio reaches a plateau close to 1 at 10 µM and higher concentrations, suggesting 
that the inherent rate of dimer formation is the same in both cases. The difference observed at low concentration may 
come from a higher concentration of bound monomers and/or the accumulation of free protein with their positively 
charged N-terminal region oriented towards the surface. 365 
 
The model presented is only a first approximation to the binding process, which is probably more complex. The bound 
species are assumed to be either fast dissociating monomers or PB forms. While the second order rate constant needed 
to fit the experimental rate of formation of the PB species strongly points to the formation of dimers, the presence of 
higher oligomers cannot be ruled out. Also the model assumes that the reaction (4) is irreversible, which would 370 
ultimately lead to an infinite concentration of PB2, since P is supplied in excess at a constant concentration. This is 
obviously not the case and the maximum concentration of PB2 must be limited, possibly by the increase in lateral 
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pressure induced by the inserted proteins (or their mutual electrostatic repulsion), which reaches a maximum level 
beyond which no further protein monomer or dimer can be inserted. 
 375 
Discussion 
All the members of the SFK have a myristoyl group attached to their N-terminal glycine residues. In addition, all of 
them, with the exception of c-Src, contain additional palmitoyl group(s) attached to cysteine residues in their SH4 
domain.  The hydrophobic acyl groups are essential for anchoring SFKs to membranes. The rest of the protein remains 
soluble and is connected to the membrane-anchored SH4 domain through the intrinsically disordered Unique domain.  380 
In the case of c-Src, insertion of a single myristoyl group does not provide enough hydrophobic energy to ensure stable 
binding.  This problem has been extensively discussed in the literature [14] [26][27][28] and the consensus view is 
currently that permanent anchoring of c-Src is achieved by the combination of hydrophobic insertion of the myristoyl 
group and electrostatic interaction of the strongly positively charged SH4 domain with negatively charged membranes. 
Here we have used SPR to characterize the kinetics of binding of Myristoylated USH3, a construct that contains the 385 
main lipid-binding region of c-Src, to immobilized liposomes. Surprisingly, two kinetically well-defined binding events 
were observed. The first one has fast association and dissociation rate constants and can be followed directly by the 
SPR response of MyrUSH3 injections. At low protein concentrations, a standard analysis of the binding curves gives an 
association constant that is in good agreement with that obtained by partition methods in similar systems. Most of the 
bound species can be washed away from the immobilized liposomes with buffer. However, a small population of a PB 390 
form of MyrUSH3 was observed. While the corresponding SPR response was only a small shift from baseline level, the 
presence of the PB species was confirmed by capture of an antiSH4 antibody by the proteins remaining on the liposome 
surface. The antibody SPR response is proportional to the PB population. The latter was retained for more than 2 h and 
could be eliminated only by detachment of the immobilized liposomes by means of detergents. When liposomes were 
not exposed to protein, no antibody was captured. 395 
 
A PB form was also observed using a synthetic myristoylated peptide containing only the SH4 domain (MyrSH4). In 
contrast, USH3 with a C12 lauryl chain instead of the C14 myristoyl chain showed no PB form, though fast association 
and dissociation processes were observed (with lower affinity than MyrUSH3). Thus from the structural point of view, 
MyrSH4 is a necessary and sufficient requirement for the observation of persistent binding. 400 
The electrostatic contribution was tested by comparing MyrUSH3 binding to neutral and negatively charged liposomes, 
and by the effect of the ionic strength. MyrUSH3 affinity and also the rate of formation of the PB form increased in 
negatively charged lipids. The effect is consistent with an electrostatically driven approach of MyrSH4 to the liposome 
surface. 
The very slow dissociation kinetics and the secondary detection using antiSH4 antibody allowed an independent 405 
analysis of the kinetics of PB species formation. The association kinetics depends on the population of the labile form 
of bound MyrUSH3 and the concentration of free MyrUSH3 during the association phase. Thus, PB formation follows 
an effective second order law, thereby suggesting that the PB form contains more than one MyrUSH3 molecule. 
 
While membrane-integrated receptor kinases are known to oligomerize, usually in response to ligand binding, and this 410 
process triggers signaling events, non-receptor kinases, like c-Src, are commonly believed to be essentially monomeric, 
even when anchored to membranes.  However, c-Src phosphorylation by a second c-Src molecule is known to occur, 
therefore at least transient contacts between c-Src molecules are functionally important.  
The kinetically detected self-association of MyrUSH3 on liposomes is in agreement with super resolution microscopy 
results with a construct containing the first 15 residues of the c-Src SH4 domain fused to photoswitchable (PS-GFP2) 415 
expressed in HeLa cells [32]. 
USH3 or its myristoylated form show no evidence of dimerization in solution, as verified in SAXS measurements 
(results not shown). Myristoylated c-Src SH4 fused to EGFP showed completely linear dependency of the fluorescence 
as a function of protein concentration on the range from 100 nM to 5 µM, indicating no observable tendency to 
aggregate in the absence of membranes (results not shown).  Therefore, we conclude that the dimerization of MyrUSH3 420 
is directly related to membrane binding.  Figure 2 shows that replacing the C14 myristoyl chain by a C12 lauryl also 
abolished dimerization, although LaurUSH3 retains the capacity to interact with lipids albeit with a lower affinity. 
These results suggest that myristoyl insertion is essential for MyrUSH3 dimerization. The strict requirement for a 
myristoyl group suggests that the insertion of the fatty acid chain in the lipid bilayer is necessary for dimerization. We 
speculate that myristoyl insertion induces a conformation of the SH4 domain that allows the dimerization to occur. 425 
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In addition, MyrUSH3 dimerization is observed in the presence of either neutral or negatively charged lipids and the 
dimer formed is irreversibly bound in both systems. The slow dissociation of MyrUSH3 dimers is consistent with the 
effectively irreversible binding of other SFKs in which two acyl chains are simultaneously inserted in the membrane.  
The enhanced binding and dimer formation observed in negatively charged lipids probably reflects the additional 
binding affinity, which results in a larger concentration of bound MyrUSH3 monomer as well as the increased local 430 
concentration of soluble MyrUSH3 close to the membrane. Membrane tethered myristoylated IDPs can be considered to 
form a soft spherical particle around the charged liposomes [33].  
The biological relevance of c-Src dimerization remains to be demonstrated but we suggest a possible functional role of 
the coexistence of a fast and a slow dissociation form of bound c-Src.  
In its resting state, inactive c-Src is found predominantly in the perinuclear region of the cell. However, upon activation 435 
c-Src accumulates in specific regions of the membrane.  Switching between monomeric and dimeric forms of c-Src 
would facilitate the fast exploration of the membrane surface until the target site is located, at which point the binding 
mode would switch to the persistent form and signaling would start. At low concentrations, myristoylated c-Src can 
probably attach and dissociate rapidly from the membrane surface, allowing fast diffusion on the 2D membrane surface 
and efficient exploration of large membrane areas. However, a local increase in c-Src concentration, for instance by 440 
high local concentrations of negatively charged lipids such as phosphatidyl inositide phosphates (PIPs), may result in 
the formation of c-Src dimers, which will remain in this particular membrane site and trans-activation will be facilitated, 
thus triggering the relevant signaling pathway.  
A similar strategy is used by transcription factors to explore large regions of DNA. These systems switch from non-
specific low affinity binding mode, to retain the transcription factor close to the DNA surface and facilitate fast one-445 
dimensional diffusion, to specific, high affinity binding at the target site. The observed dual lipid binding mode of c-Src 
suggest a similar mechanism in which fast dissociation allow diffusion close to the 2D surface of the membrane, while 
dimerization fixes c-Src at the target site to initiate downstream signaling.  
 
 450 
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Figure Captions 
 
 535 
Figure 1 Domain structure of c-Src. 
 (a) Domain structure of c-Src. Lipid interacting regions (SH4, ULBR, RT loop) are highlighted. (b) MyrUSH3 Sequence. Residues 1 
to 85 are intrinsically disordered and include the SH4 and Unique domains. Residues 88–150 correspond to SH3 domain and 151–
156 to the His6Tag. 
 540 
Figure 2 Binding of myristoylated and laurylated peptides to liposomes. 
 (a) Comparison of binding of 50 µM MyrSH4 and 100 µM MyrUSH3 to liposomes. DOPC:DOPG 2:1 liposomes, in 50 mM NaP, 
150 mM NaCl.(b) Comparison of the binding of 20 µM LaurUSH3 with that of 1 µM and 20µM MyrUSH3. DMPC:DMPG 2:1 
liposomes, in 50mM NaP and 150 mM NaCl. (c) Binding of 10 µM MyrUSH3 to DMPC or DMPC: DMPG 2:1 liposomes in 50mM 
NaP and 150 mM NaCl  (d) Binding of 2 µM MyrUSH3 to DMPC:DMPG 2:1 liposomes in the presence or absence of 150 mM 545 
NaCl. In (a-d), the first curve corresponds to direct SPR peptide response, while the second is that of the secondary antibody 
detection.  
 
 
Figure 3 Experimental scheme for the kinetics study  of persistent forms of MyrUSH3. 550 
 (a) The build-up of antibody detectable MyrUSH3 over liposomes is monitored over time by varying the association time using a 
constant dissociation time.  (b) Dissociation is followed by varying the dissociation time after a constant association time. 
 
 
Figure 4 SPR sensograms and indirectly detected dissociation curves of persistent forms of MyrUSH3.  555 
Direct and antibody detected SPR responses of 60s/350s association/dissociation of MyrUSH3 (between 2µM and 20µM) on (a) 
DMPC and (b) DMPC:DMPG liposomes respectively. Dissociation from  (c) DMPC and (d) DMPC:DMPG, detected by antibody 
secondary detection, following 60 s MyrUSH3 association time and variable dissociation times.*Baseline corresponds to an identical 
experiment in which the protein was omitted. 
 560 
 
Figure 5 Indirectly detected binding curves of persistent forms of MyrUSH3. 
Build-up of persistent MyrUSH3 on (a) DMPC and (b) DMPC:DMPG, detected by antibody secondary detection, using a constant 
dissociation time of 350 s. The continuous curves correspond to the best-fits of the equation shown. Linear concentration dependence 
of k'on. for binding to (c) DMPC and (d) DMPC: DMPG liposomes. *Baseline corresponds to an identical experiment in which the 565 
protein was omitted. ** Duplicated results at 10µM are shown; the error bar is shown in (c) and (d). 
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Figure 1 Domain structure of c-Src. 
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Figure 2 Binding of myristoylated and laurylated peptides to liposomes. 
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Figure 3  Experimental scheme for the kinetics study  of persistent forms of MyrUSH3. 
 
 
 
Figure 4 SPR sensograms and indirectly detected dissociation curves of persistent forms of MyrUSH3.  595 
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Figure 5 Indirectly detected binding curves of persistent forms of MyrUSH3. 
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